Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Giant Biogene Holding CoHKSE:02367 +1.32%85 Return-on-Tangible-Equity is 15.00% as of Dec. 2025, which is 69% below its 10-year median of 48.51. GuruFocus rates HKSE:02367 with a GF Score™ of 85/100 and a GF Value™ of HK$68.03 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,904 Consumer Packaged Goods companies, Giant Biogene Holding Co ranks better than 76.16% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Giant Biogene Holding Co's annualized net income for the quarter that ended in Dec. 2025 was HK$1,584 Mil. Giant Biogene Holding Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$10,484 Mil. Therefore, Giant Biogene Holding Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 15.10%.
The historical rank and industry rank for Giant Biogene Holding Co's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:02367'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 17.9 Med: 48.51 Max: 114.69
Current: 17.9
During the past 7 years, Giant Biogene Holding Co's highest Return-on-Tangible-Equity was 114.69%. The lowest was 17.90%. And the median was 48.51%.
HKSE:02367's Return-on-Tangible-Equity is ranked better than 76.16% of 1904
companies
in the Consumer Packaged Goods industry
Industry Median: 8.045
vs HKSE:02367: 17.90
Giant Biogene Holding Co (HKSE:02367) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Giant Biogene Holding Co Return-on-Tangible-Equity Related Terms
Giant Biogene Holding Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Giant Biogene Holding Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Giant Biogene Holding Co Return-on-Tangible-Equity Chart
HKSE:02367 vs PG, CL, EL: Return-on-Tangible-Equity Comparison
For the Household & Personal Products subindustry, Giant Biogene Holding Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Giant Biogene Holding Co Return-on-Tangible-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Giant Biogene Holding Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 15.00% mean?
Giant Biogene Holding Co (HKSE:02367) has a Return-on-Tangible-Equity of 15.00% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Giant Biogene Holding Co and its competitors. This is 69% below median its historical median of 48.51. Over the past decade, Giant Biogene Holding Co's Return-on-Tangible-Equity has ranged from 17.90 to 114.69. According to the industry distribution chart, Giant Biogene Holding Co ranks #454 out of 1904 companies in the Consumer Packaged Goods industry, placing it in the top 23.8%.
Is Giant Biogene Holding Co's Return-on-Tangible-Equity too high?
Giant Biogene Holding Co's current Return-on-Tangible-Equity of 15.00% is 69% below median its 10-year median of 48.51. Over the past 10 years, this metric has ranged from a low of 17.90 to a high of 114.69. The Consumer Packaged Goods industry median Return-on-Tangible-Equity is 8.05. Giant Biogene Holding Co's value of 15.00% is 86.5% above this industry median. Based on the distribution chart, Giant Biogene Holding Co ranks #454 out of 1904 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Giant Biogene Holding Co has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Giant Biogene Holding Co's Return-on-Tangible-Equity compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Giant Biogene Holding Co ranks #454 out of 1904 companies for Return-on-Tangible-Equity. This places Giant Biogene Holding Co in the top 24% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 8.05. Giant Biogene Holding Co's value of 15.00% is 86.5% above this benchmark. Historically, Giant Biogene Holding Co's own Return-on-Tangible-Equity has ranged from 17.90 to 114.69 over the past decade. While the company's 10-year median is 48.51 vs. the industry median of 8.05, Giant Biogene Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Consumer Packaged Goods company?
The median Return-on-Tangible-Equity among Consumer Packaged Goods companies is 8.05, based on 1,904 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Giant Biogene Holding Co's current Return-on-Tangible-Equity of 15.00% is 86.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Giant Biogene Holding Co and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Equity is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Giant Biogene Holding Co's current Return-on-Tangible-Equity is 15.00%, which is 69% below median its own 10-year median of 48.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Giant Biogene Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Giant Biogene Holding Co (HKSE:02367) is currently considered Possible Value Trap. The stock's GF Value™ is HK$68.03, compared to a current price of HK$24.48 — trading 64% below its estimated fair value. The current Return-on-Tangible-Equity is 15.00%, which is 69% below median its 10-year median of 48.51 and 86.5% above the Consumer Packaged Goods industry median of 8.05. Giant Biogene Holding Co's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Giant Biogene Holding Co (HKSE:02367), the current Return-on-Tangible-Equity is 15.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Giant Biogene Holding Co (HKSE:02367) Overvalued in 2026?
Based on GuruFocus' analysis, Giant Biogene Holding Co stock appears to be undervalued.
The current stock price of HK$24.48 is trading 64% below its estimated GF Value™ of HK$68.03.
GuruFocus considers Giant Biogene Holding Co to be Possible Value Trap.
Key valuation signals for HKSE:02367:
Return-on-Tangible-Equity: 15.00% (69% below median its 10-year median of 48.51)
GF Value™: HK$68.03 vs. price of HK$24.48 (64% below fair value)
Industry Position: 86.5% above the Consumer Packaged Goods median (#454 of 1904)
No single metric tells the full story. See the HKSE:02367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Giant Biogene Holding Co Ltd designs, develops, and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenoside technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop & manufacture multiple types of recombinant collagen & rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty & health properties such as skin repair, anti-aging, whitening, moisturizing, & immunity improvement, with a broad range of applications in the beauty & health sectors. The group is organised into a single business unit that mainly includes the research, development, manufacture, & sale of bioactive material-based beauty & health products.
85GF Score
Get the complete analysis for HKSE:02367
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02367 has been successfully added to your 
